Inari Medical Inc expected to post earnings of 1 cent a share - Earnings Preview

Inari Medical

27/02/2024 24:35

* Inari Medical Inc  NARI.OQ   NARI.O  is expected to show a
rise
in quarterly revenue when it reports  results on February 28 for
the period ending December 31 2023
    * The Irvine California-based  company is expected to report
a
22.3% increase in revenue to $131.789 million from $107.77
million a year ago, according to the mean estimate from 10
analysts, based on LSEG data.The company's guidance on January 9
2024, for the period ended December 31, was for revenue of
$132.000 million.
    * ​LSEG's mean analyst estimate for Inari Medical Inc is for
earnings of 1 cent per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Inari
Medical Inc
is $79.50​, above​ its last closing price of $56.37. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  0.00        0.00       0.05      Beat    1,026.
                                                        1
 Jun. 30 2023  -0.13       -0.13      0.04      Beat    131.6
 Mar. 31 2023  -0.22       -0.23      -0.04     Beat    82.3​
 Dec. 31 2022  -0.17       -0.17      -0.11     Beat    35.8
 ​​Sep.        -0.26       -0.25      -0.19     Beat    25.1
 30 2022                                                
 Jun. 30 2022  -0.23       -0.23      -0.19     Beat    17.4​
 Mar. 31 2022  -0.09       -0.09      -0.06     Beat    34.5
 Dec. 31 2021  0.06        0.03       0.02      Missed  -23.1
 This summary was machine generated February 27 at 00:35 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)